Clinical Scorecard: Validation of T1ρ Mapping Techniques for Evaluating Hepatic Fibrosis in Individuals with Chronic Liver Conditions

At a Glance

Key Highlights

• Hepatic fibrosis is a critical prognostic factor in CLD, especially with ongoing inflammation as in MASH.
• Non-invasive imaging methods, especially MR-elastography (MRE), are key alternatives to liver biopsy for fibrosis staging.
• T1ρ mapping is a promising MRI technique potentially more accurate and robust than conventional T1, ECV, and T2 mapping for fibrosis evaluation.

Guideline-Based Recommendations

Diagnosis

• Use MR-elastography (MRE) as the current non-invasive standard for liver fibrosis assessment.
• Consider T1ρ mapping as an emerging quantitative MRI biomarker for hepatic fibrosis across the CLD spectrum.
• Employ serological markers and panels as adjuncts but recognize their limited specificity due to confounding factors.

Management

• Early diagnosis and follow-up of hepatic fibrosis are essential for managing CLD patients.
• Incorporate quantitative MRI techniques, including T1ρ mapping, to improve non-invasive fibrosis evaluation.

Monitoring & Follow-up

• Use serial imaging with MRE and potentially T1ρ mapping to monitor fibrosis progression or regression.
• Calculate non-invasive fibrosis scores (fibrosis-4 index, APRI, de Ritis ratio, MELD) alongside imaging for comprehensive assessment.

Risks

• Liver biopsy, while definitive, carries risks and is invasive; non-invasive imaging reduces these risks.
• Serological markers may be influenced by extrahepatic conditions, limiting diagnostic accuracy.

Patient & Prescribing Data

Patients with chronic liver disease undergoing MRI for fibrosis assessment

T1ρ mapping offers a non-invasive, potentially more accurate imaging biomarker for hepatic fibrosis, facilitating early diagnosis and monitoring without additional hardware requirements of MRE.

Clinical Best Practices

• Perform MRI on a 1.5-Tesla scanner with appropriate coils and sequences including MRE, PDFF, T1, T2, and T1ρ mapping.
• Acquire quantitative maps in a single matched slice at the portal vein bifurcation with breath-holding to reduce motion artifacts.
• Analyze multiple liver segments with carefully placed ROIs avoiding vessels and artifacts to ensure representative sampling.
• Calculate ECV corrected for hematocrit using pre- and post-contrast T1 relaxation times for fibrosis assessment.
• Use blinded, experienced radiologists for image analysis to reduce bias.

References

• MR-elastography accuracy meta-analyses
• Preclinical study of T1ρ as biomarker of hepatic fibrosis
• Technical details of MRI sequences and quantitative mapping